The concept of Helicobacter pylori had an active intraday trend on the 12th. As of the close, Nanjing Hicin Pharmaceutical Co.Ltd(300584) “20cm” limit, Sailong Pharmaceutical Group Co.Ltd(002898) , Zhejiang Yatai Pharmaceutical Co.Ltd(002370) 10cm limit, Hybio Pharmaceutical Co.Ltd(300199) , Guangzhou Wondfo Biotech Co.Ltd(300482) , Beijing Strong Biotechnologies Inc(300406) and so on increased by more than 8%. It is worth noting that Zhejiang Yatai Pharmaceutical Co.Ltd(002370) has increased the limit for five consecutive trading days recently, Sailong Pharmaceutical Group Co.Ltd(002898) three connected boards and Nanjing Hicin Pharmaceutical Co.Ltd(300584) two connected boards.
In terms of news, recently, the U.S. Department of health and human services released the 15th edition of carcinogen report, adding 8 kinds of carcinogens. In this report, Helicobacter pylori chronic infection is listed as a clear human carcinogen.
According to the 2001-2014 national Helicobacter pylori survey, the Helicobacter pylori infection rate in China is between 40% – 90%, with an average of 59%, which is equivalent to one person in every two people in China. Affected by the above news, the concept stocks for the prevention and treatment of Helicobacter pylori have been active recently.
According to incomplete statistics, there are no fewer than 10 “anti Helicobacter pylori concept stocks” in the market. In addition to Juneyao Grand Healthy Drinks Co.Ltd(605388) , Beijing Scitop Bio-Tech Co.Ltd(300858) , Shanghai Jiaoda Onlly Co.Ltd(600530) , there are Guobang Pharma Ltd(605507) , Zhejiang Yatai Pharmaceutical Co.Ltd(002370) , Shanshui technology, Guangzhou Wondfo Biotech Co.Ltd(300482) , Qingdao Vland Biotech Inc(603739) , Pony Testing International Group Co.Ltd(300887) , Boji Medical Technology Co.Ltd(300404) .
On the concept of anti Helicobacter pylori, many companies answered investors’ questions on the interactive platform.
Among them, Guobang Pharma Ltd(605507) indicates that clarithromycin preparation is an important part of the mainstream combined regimen for the treatment of Helicobacter pylori. Clarithromycin is one of the main pharmaceutical raw materials of the company and is sold to China’s major international clarithromycin preparation manufacturers. The company and Abbott group are actively promoting the cooperative production of clarithromycin semi preparations.
Zhuhai Rundu Pharmaceutical Co.Ltd(002923) said that the indications specified in the product manual of rabeprazole sodium enteric coated capsule of the company are: suitable for gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, Zollinger Ellison syndrome, and auxiliary for eradicating Helicobacter pylori in patients with gastric ulcer or duodenal ulcer.
According to Shanshui technology, in the pharmaceutical intermediate market, the company has produced antidepressant antipyrine, Helicobacter pylori inhibitor tetoprazole, xinminle / xinminling, etc.
Pony Testing International Group Co.Ltd(300887) said that at present, the company is developing a rapid detection kit for Helicobacter pylori, which is mainly used for rapid screening of Helicobacter pylori in saliva.
Boji Medical Technology Co.Ltd(300404) said that the company has served two Helicobacter pylori related drugs in the past two years, one of which is a diagnostic drug. The relevant tests have been completed and the data have been submitted to the sponsor; The other is therapeutic drugs, which is currently in the final stage and is in the process of collating data with the sponsor.
Qingdao Vland Biotech Inc(603739) said that the company’s probiotics against Helicobacter pylori are still in the early research and development stage, and the research and development progress is very uncertain, with the risk of research and development failure.
